Study Finds Immunotherapy, Targeted Therapy Combination May Be Option for Advanced Kidney Cancer

Ajjai Alva, MD, MS finds that the combination of pembrolizumab and bevacizuma were tolerable and effective in treating patients with metastatic kidney cancer.